---
title: "Parkinson's Disease, Diagnostic Observations (PADDO)"
nct_id: NCT01249768
overall_status: UNKNOWN
sponsor: Radboud University Medical Center
study_type: OBSERVATIONAL
primary_condition: "Parkinson's Disease"
countries: Netherlands
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01249768.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01249768"
ct_last_update_post_date: 2016-03-31
last_seen_at: "2026-05-12T06:51:04.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Parkinson's Disease, Diagnostic Observations (PADDO)

**Official Title:** Observational Study Assessing the Diagnostic Contribution of 3-Tesla MRI, CSF Analysis and a Second Opinion in a Specialized Movement Disorder Centre, in Differentiating Between Parkinson's Disease and Atypical Parkinsonism

**NCT ID:** [NCT01249768](https://clinicaltrials.gov/study/NCT01249768)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 150
- **Lead Sponsor:** Radboud University Medical Center
- **Conditions:** Parkinson's Disease, Atypical Parkinsonism
- **Start Date:** 2010-07
- **Completion Date:** 2018-07
- **CT.gov Last Update:** 2016-03-31

## Brief Summary

Background:

Parkinson's Disease and the Atypical Parkinsonian Disorder (like Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration, Lewy Body Dementia) are disease entities with partly common symptomatology. Especially very early in the course of disease, the differentiation between both disease entities can be challenging, even for specialists in the field of movement disorder. However, the establishment of a correct diagnosis is very important for adequate patientcounseling, treatment and the correct inclusion of patients in research trials. Ancillary diagnostic investigations are looked upon to aid in this diagnostic dilemma.

Objective:

To investigate the value of ancillary diagnostic investigations, more specific MRI, analysis of cerebrospinal fluids and a second opinion in a specialized movement disorder centre, to differentiate Parkinson's disease and the Atypical Parkisonisonian disorder.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Hypokinetic rigid syndrome
* Disease duration of maximum 36 months

Exclusion Criteria:

* Probable diagnosis of PD without any red flags
* Probable diagnosis MSA
* Probable diagnosis PSP
* Diagnosis CBD
* Diagnosis DLB
* Probable diagnosis Vascular Parkinsonism
* Other neurodegenerative disease than parkinsonism
* A prior history of brain surgery
* Instable comorbidity
```

## Arms

- **Cohort** — The cohort will consist of 150 patients with a hypokinetic rigid syndrome and a disease duration of maximum 36 months

## Primary Outcomes

- **percentage of correct diagnosis for each of the specified ancillary investigations** _(time frame: 36 months)_ — Percentage of correct diagnosis for each of the specified ancillary investigations to differentiate between either PD or atypical parkinsonism

## Secondary Outcomes

- **Percentage of correct diagnosis for each of the specified ancillary investigations** _(time frame: 36 months)_

## Locations (1)

- Radboud University Medical Centre, Nijmegen, Netherlands — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.radboud university medical centre|nijmegen||netherlands` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01249768.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01249768*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*